Medical Charge Card
Dear Sir:
With the introduction of 'universal' Medicare in Canada, the great majority of physicians have little choice at the present time but to bill the provincial paying agency for medical services rendered.
Inevitably the old adage that 'He who pays the piper calls the tune' has proved to be true and government is now dictating to physicians in respect of fees and schedules of benefits, extra-billing, and now in one province the minimum amount of time which must be spent when examining a patient.
While there are many advantages in a health care system where the majority of patients have insurance coverage, the economic and political consequences of the provision of a government monopoly health plan are potentially disastrous. The medical profession in Canada is becoming subservient to government bureaucracy and one way to escape from the trap is to deal directly with our patients.
In many medical offices it is impracticable to invoice individual patients for services rendered, but with the increasing use of credit cards there is no reason why a group of physicians who are determined to deal directly with their patients should not take advantage of Chargex, Master Charge, American Express, etc.
I should be interested to hear from those physicians who support the concept of the use of a medical charge card, or favour entering into some form of association with established credit card organizations in Canada.
A. Geoffrey Dawrant, M.B., B.Ch.
Edmonton, Alberta
Critique de l'antipsychiatrie
Monsieur le redacteur en chef, Je voudrais attirer l'attention des lecteurs de la Revue de l' association des psychiatres du 
An Unusual Adverse Reaction With Butyrophenone Therapy
Dear Sir: Haloperidol, a butyrophenone preparation, has been increasingly used for the rapid control of the acute symptoms of schizophrenia (2), manic states (5), Gilles de la Tourette's syndrome (3, 4) and as an antiemetic in obstetric patients.
Recently an unusual adverse reaction was encountered here -urinary retention associated with haloperidol therapy at St. Mary's Hospital (SMH), Montreal. This appeared to be associated with a prodromal reaction of abdominal fullness, discomfort, and constipation. The following is a review of the case histories with a discussion.
Case I
A 37-year-old female was admitted to SMH on 21 February 1973 with symptoms of agitation, excitement and elation. A full physical examination, including neurological evaluation and laboratory investigations were essentially unremarkable. The patient was placed on chlorpromazine 600 mg daily. Six days after admission, as the patient's symptoms of excitement had not been fully controlled chlorpromazine was discontinued and haloperidol 40 mg daily was instituted, and the patient's excitement and manic behaviour decreased. On March 3 benztropine mesylate was started because of parkinsonian symptoms, and haloperidol was decreased to 30 mg daily. Eighteen days later the patient complained of symptoms of fullness and discomfort in the abdominal region and of constipation. Examination revealed her bladder to be grossly distended and painful to palpitation. However, she was able to pass urine later in the day and haloperidol was continued as before, and benztropine mesylate was discontinued. The following day, the patient again complained of the same difficulty in voiding and on re-examination was found to have a distended bladder. Haloperidol was reduced to 15 mg daily and that afternoon the patient voided. An examination during this period did not disclose any urinary infection or pathology of the genito-urinary tract. The next day the patient complained of stomach fullness and inability to void. Carbachol 0.25 mg was administered subcutaneously without result and she was catheterized that evening. She continued to experience symptoms of abdominal fullness, discomfort and constipation, and haloperidol was discontinued. From the date of cessation of haloperidol therapy the patient no longer complained of urinary retention or symptoms of fullness, discomfort and constipation.
Case II
A 35-year-old unemployed single woman was admitted to SMH on 16 February 1973, with psychotic symptoms. On physical examination, the only positive finding was that of a marked congenital hip deformity and resulting difficulty in ambulation. On the basis of lack of response to other neuroleptics the patient was started on haloperidol 10 mg daily on 18 April 1973. Two days later, the patient developed prodromal symptoms of abdominal fullness, discomfort and constipation, with urinary retention. Haloperidol was therefore discontinued and her symptoms of retention disappeared. A full examination of urinary function proved to be entirely within normal limits as had been the previous laboratory examinations. Two days later, haloperidol was re-started in a dose of 10 mg
